Skip to main content
. Author manuscript; available in PMC: 2012 Mar 16.
Published in final edited form as: Curr Mol Med. 2012 Feb;12(2):163–176. doi: 10.2174/156652412798889063

Fig. (2).

Fig. (2)

Decrease in serum VEGF (A) and HGF (B) levels by orally administrated EGCG in breast cancer patients under radiotherapy. Breast cancer patients (n=5) received three oral doses of EGCG (400 mg) daily for 8 weeks (w) during the 5-w radiotherapy cycles and 3-w afterwards. The breast cancer patients (n=5) in control group who received radiotherapy alone during the 8-w without EGCG treatment. Blood samples were collected at 0-h, at 0 w (immediately before EGCG administration), and at 1-w, 2-w, 4-w, 6-w and 8-w, at 2-h after the EGCG dose (2-h fasting blood samples). The serum VEGF and HGF levels were determined by ELISA. Values are shown as mean ± SD for each group from 0-h (0-w) to 8-w. All samples were assayed in triplicate and the mean of the values was calculated. Significance levels were determined using the ANOVA and Bonferroni test or Student’s t-test. * P < 0.05; **P < 0.01; and *** P < 0.001.